Literature DB >> 23292862

High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer.

Christos Perisanidis1, Gabriela Kornek, Paul W Pöschl, Daniel Holzinger, Katharina Pirklbauer, Christian Schopper, Rolf Ewers.   

Abstract

With growing evidence on the role of inflammation in carcinogenesis, the presence of a systemic inflammatory response has been proposed as having prognostic significance in a wide range of cancers. The aim of the study was to assess the value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in predicting disease-specific survival (DSS) in patients with oral cancer undergoing preoperative chemoradiotherapy. A cohort of 97 patients with locally advanced oral squamous cell carcinoma receiving preoperative chemoradiotherapy was retrospectively examined. The impact of NLR and other potential prognostic factors on DSS was assessed with the Kaplan-Meier method and multivariate Cox regression analysis. Sixty-nine patients had a high pretreatment NLR, with NLR > 1.9 considered as high according to receiver operating characteristic curve analysis. In univariate analysis, high pretreatment NLR (p = 0.018), positive perineural invasion (p < 0.001) and advanced pathologic TNM stage after neoadjuvant therapy (p < 0.001) were predictive of shorter DSS. In multivariate analysis, advanced pathologic TNM stage after neoadjuvant therapy (HR 1.71, 95 % CI 1.17-2.48, p = 0.005), positive perineural invasion (HR 3.67, 95 % CI 1.11-12.13, p = 0.033) and high pretreatment NLR (HR 10.37, 95 % CI 1.28-84.08, p = 0.029) remained independently associated with poor DSS. A high pretreatment NLR is a significant independent predictor of shorter DSS in patients with oral cancer receiving preoperative chemoradiotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 23292862     DOI: 10.1007/s12032-012-0334-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  41 in total

1.  Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma.

Authors:  Jian-Rong He; Guo-Ping Shen; Ze-Fang Ren; Han Qin; Cui Cui; Ying Zhang; Yi-Xin Zeng; Wei-Hua Jia
Journal:  Head Neck       Date:  2012-02-09       Impact factor: 3.147

Review 2.  Global epidemiology of oral and oropharyngeal cancer.

Authors:  Saman Warnakulasuriya
Journal:  Oral Oncol       Date:  2008-09-18       Impact factor: 5.337

3.  Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma.

Authors:  Karim J Halazun; Mark A Hardy; Abbas A Rana; David C Woodland; Elijah J Luyten; Suhari Mahadev; Piotr Witkowski; Abbey B Siegel; Robert S Brown; Jean C Emond
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

4.  Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.

Authors:  G Q Phan; P Attia; S M Steinberg; D E White; S A Rosenberg
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

5.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

6.  Neoadjuvant concurrent radiochemotherapy followed by surgery in advanced oral squamous cell carcinoma (OSCC): a retrospective analysis of 207 patients.

Authors:  Kolja Freier; Michael Engel; Katja Lindel; Christa Flechtenmacher; Joachim Mühling; Stefan Hassfeld; Christof Hofele
Journal:  Oral Oncol       Date:  2007-03-09       Impact factor: 5.337

7.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

Review 8.  Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression.

Authors:  Zhifu Sun; Ping Yang
Journal:  Lancet Oncol       Date:  2004-03       Impact factor: 41.316

9.  Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma.

Authors:  Sunil D Khandavilli; Padraig O Ceallaigh; Christopher J Lloyd; Rhiannon Whitaker
Journal:  Oral Oncol       Date:  2009-06-06       Impact factor: 5.337

10.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

View more
  39 in total

1.  Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma.

Authors:  Saleh Rachidi; Kristin Wallace; John M Wrangle; Terry A Day; Anthony J Alberg; Zihai Li
Journal:  Head Neck       Date:  2015-09-28       Impact factor: 3.147

2.  Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer.

Authors:  Derya Kivrak Salim; Hasan Mutlu; Melek Karakurt Eryilmaz; Ozan Salim; Fatma Yalçin Musri; Deniz Tural; Şeyda Gündüz; Hasan Şenol Coşkun
Journal:  Mol Clin Oncol       Date:  2015-05-04

3.  Standardized pretreatment inflammatory laboratory markers and calculated ratios in patients with oral squamous cell carcinoma.

Authors:  Martin Grimm; Johan Rieth; Sebastian Hoefert; Michael Krimmel; Sven Rieth; Peter Teriete; Susanne Kluba; Thorsten Biegner; Adelheid Munz; Siegmar Reinert
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-29       Impact factor: 2.503

4.  Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.

Authors:  Edgar Selzer; Anja Grah; Gregor Heiduschka; Gabriela Kornek; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2015-01-13       Impact factor: 3.621

5.  Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma.

Authors:  Kenichi Shinagawa; Souichi Yanamoto; Tomofumi Naruse; Akiko Kawakita; Kota Morishita; Yuki Sakamoto; Satoshi Rokutanda; Masahiro Umeda
Journal:  Pathol Oncol Res       Date:  2016-10-15       Impact factor: 3.201

Review 6.  Immunomethylomics: A Novel Cancer Risk Prediction Tool.

Authors:  Karl T Kelsey; John K Wiencke
Journal:  Ann Am Thorac Soc       Date:  2018-04

7.  Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Laryngeal Carcinoma.

Authors:  Beyhan Yılmaz; Engin Şengül; Aylin Gül; Ulaş Alabalık; Fazıl Emre Özkurt; Mehmet Akdağ; İsmail Topçu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-29

8.  Neutrophil-to-lymphocyte ratio as a prognostic factor for pharyngocutaneous fistula after total laryngectomy.

Authors:  F T Aires; R A Dedivitis; M A V Kulcsar; D M Ramos; C R Cernea
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-02       Impact factor: 2.124

9.  The pre-treatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and red cell distribution width predict prognosis in patients with laryngeal carcinoma.

Authors:  Medine Kara; Sema Uysal; Uğur Altinişik; Sibel Cevizci; Oğuz Güçlü; Fevzi Sefa Dereköy
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-12       Impact factor: 2.503

10.  Prognostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Head and Neck Malignancies.

Authors:  Yanish Bhashkar Seetohul; Vishwambhar Singh; Rajiv Kumar Jain; Ashvanee Kumar Chaudhary
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.